Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies

Next Previous
Trial Profile

A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan (Primary) ; Busulfan (Primary) ; Fludarabine (Primary) ; Mesna (Primary) ; Cyclophosphamide; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
  • Indications Acute myeloid leukaemia; Graft-versus-host disease; Lymphoid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms ACCESS

Most Recent Events

  • 04 Jun 2024 Results (n=70) ,presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 01 Feb 2023 Planned number of patients changed from 200 to 300.
  • 05 Jan 2023 Planned number of patients changed from 180 to 200.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top